改良根治术联合腋窝筋膜瓣组织成型治疗乳腺癌的临床观察

Effect of modified radical mastectomy combined with axillary fascial flap tissue forming on breast cancer

目的 研究乳腺癌改良根治术联合腋窝筋膜瓣组织成型治疗乳腺癌的临床效果。方法 选择2019年3月至2022年7月郑州大学第一附属医院收治的72例乳腺癌患者进行研究。按随机数字表法将患者分为对照组与观察组,每组36例。对照组患者单纯行改良根治术治疗,观察组患者行改良根治术联合腋窝筋膜瓣组织成型治疗。比较两组患者手术情况和并发症发生情况。结果 两组患者手术时间和住院时间比较,差异未见统计学意义(P>0.05)。观察组术后引流量少于对照组,持续引流时间短于对照组(P<0.05)。两组切口破裂发生率比较,差异未见统计学意义(P>0.05)。观察组淋巴水肿、肩关节功能障碍以及血清肿发生率均低于对照组(P<0.05)。结论 乳腺癌患者进行改良根治术治疗时联合腋窝筋膜瓣组织成型能有效缩短术后引流量和引流时间,降低术后血清肿的发生率,术后并发症发生率更低。

Objective To study the clinical effect of modified radical mastectomy combined with axillary fascial flap tissue forming on breast cancer.Methods Seventy-two patients with breast cancer admitted to the First Affiliated Hospital of Zhengzhou University from March 2019 to July 2022 were selected in the clinical study.The patients were divided into control group and observation group according to the random number table,with 36 cases in each group.The patients in the control group received only modified radical surgery,and the patients in the observation group were treated with modified radical surgery combined with axillary fascial flap tissue molding.The surgical conditions and complications of the two groups were compared.Results There was no significant difference between the two groups in surgical time or hospital stay(P>0.05).The postoperative drainage flow in the observation group was less than that in the control group,and the continuous drainage time was shorter than that in the control group(P<0.05).There was no significant difference in the incidence of wound rupture between the two groups(P>0.05).The incidences of lymphedema,shoulder joint dysfunction,and seroma in the observation group were lower than those in the control group(P<0.05).Conclusions The modified radical mastectomy combined with axillary fascial flap tissue molding can effectively shorten the postoperative drainage flow and drainage time,reduce the incidence of postoperative seroma,and lower the incidence of postoperative complications in patients with breast cancer.